Clinical trials: Neuroectodermal Tumor
Solid Tumor, Lymphoma
Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.
This is a single arm Phase 2 study of the combination of adenoviral p53 (Ad-p53) gene therapy administered intra-tumorally with approved immune checkpoint inhibitors in patients with recurrent or metastatic cancers.
- Trial name
- NCT03544723
- Testing
- Ad-p53
- Where
- 3 sites in United States
- Volunteers
- 40 people
- Sponsor
- MultiVir, Inc.
Severe Combined Immunodeficiency, Malignancy, Hematologic
Long Term Follow Up Of Patients Who Have Received Gene Therapy Or Gene Marked Products
This protocol (GENEFU) provides a mechanism for the 15-year followup period that the FDA requires for all participants in gene transfer protocols and assures that adequate followup can be maintained for a wide variety of…
- Conditions
- Severe Combined Immunodeficiency, Malignancy, Hematologic, Neuroblastoma, Neoplasm
- Trial name
- NCT00695279
- Testing
- Venipuncture
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- St. Jude Children's Research Hospital
Locally Advanced Metastatic BRAF Mutant Melanoma
Safety and Efficacy of LEE011 and LGX818 in Patients With BRAF Mutant Melanoma.
To evaluate the safety, tolerability and efficacy of LEE011 and LGX818 when administered orally to patients with BRAF mutant melanoma.
- Trial name
- NCT01777776
- Testing
- LEE011, LGX818
- Where
- 9 sites in United States, Australia and 2 more
- Volunteers
- 28 people
- Sponsor
- Array BioPharma
Breast Cancer, Endometrial Cancer
BI 2536 in Treating Patients With Recurrent or Metastatic Solid Tumors
RATIONALE: BI 2536 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying the side effects and how well BI 2536 works in treating patients with…
- Conditions
- Breast Cancer, Endometrial Cancer, Head and Neck Cancer, Melanoma (Skin)
- Trial name
- NCT00526149
- Testing
- BI 2536, high performance liquid chromatography, mass spectrometry
- Where
- Belgium
- Volunteers
- 76 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Uveal Melanoma
Neoadjuvant Immunotherapy for Patients With High-risk Eye Melanoma
The goal of this clinical trial is to investigate the safety and feasibility of neoadjuvant immunotherapy for patients with high-risk uveal melanoma.
- Trial name
- NCT07501117
- Testing
- Nivolumab & Ipilimumab
- Where
- Denmark
- Volunteers
- 15 people
- Sponsor
- Inge Marie Svane
Neuroendocrine Tumors Unresectable, Neuroendocrine Tumor Metastatic
Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Tumors
This study is Phase I/IIa First-in-Human Study of [212Pb]VMT-α-NET Targeted Alpha-Particle Therapy for Advanced SSTR2 Positive Tumors
- Conditions
- Neuroendocrine Tumors Unresectable, Neuroendocrine Tumor Metastatic, Gastroenteropancreatic Neuroendocrine Tumor, Bronchial Neuroendocrine Tumor
- Trial name
- NCT05636618
- Testing
- [203Pb]VMT-α-NET, [212Pb]VMT-α-NET
- Where
- 20 sites in United States
- Volunteers
- 300 people
- Sponsor
- Perspective Therapeutics
Neuroblastoma
NB2013-HR German (GPOH) / Dutch (DCOG) Trial
Although the five year survival rate of children with high risk neuroblastoma have increased over the last three decades from 4 to 44 % (1), neuroblastoma is the second most frequent cause for cancer related death in childhood…
- Trial name
- NB2013-HR (NCT02641782)
- Testing
- antibody ch14.18, GM-CSF, IL-2 i.v.
- Where
- Germany
- Volunteers
- 3 people
- Sponsor
- University of Cologne
Glioblastoma
A Study Evaluating the Safety, Pharmacokinetic and Anti-tumor Activity of RO7428731 in Participants With Glioblastoma
This is an open-label, multicenter study to assess safety, tolerability, pharmacokinetics (PK), immunogenicity, pharmacodynamics (PD), and preliminary efficacy of RO7428731 administered as a monotherapy in participants with newly…
- Trial name
- NCT05187624
- Testing
- RO7428731
- Where
- 8 sites in United States, Australia and 3 more
- Volunteers
- 36 people
- Sponsor
- Hoffmann-La Roche
Glioma
Simulation-Based Caregiving Skills Training for Family Members of High Grade Glioma Patients
Family caregivers of patients with a primary brain tumor experience a high caregiving load including assistance with activities of daily living without any formal training.
- Trial name
- NCT05511324
- Testing
- Questionnaires, Caregiver Assessment
- Where
- United States
- Volunteers
- 124 people, healthy volunteers welcome
- Sponsor
- M.D. Anderson Cancer Center
Melanoma
Evaluation of the Effects of Local Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in Adjuvant Administration on Dendritic Cells in Skin of Melanoma Patients and in Sentinel Lymph Nodes: MEL38
Goal: To characterize the cellular events that occur in vivo after vaccination with an emulsion of GMCSF-in-adjuvant. Design: Open-label, single dose study in two stages.
- Trial name
- MEL38 (NCT00912574)
- Testing
- GM-CSF-in-adjuvant, Montanide ISA-51, GM-CSF and Montanide ISA-51
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- University of Virginia
Neuroblastoma
Local Control With Reduced-dose Radiotherapy for High-Risk Neuroblastoma
The purpose of this study is to give 12T a smaller dose of radiation in order to decrease these late side effects.
- Trial name
- NCT02245997
- Testing
- External beam radiotherapy, proton beam RT
- Where
- United States
- Volunteers
- 78 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Brain and Central Nervous System Tumors
Motexafin Gadolinium With MRI-Guided Surgery in Treating Patients With High-Grade Gliomas
RATIONALE: New imaging procedures such as the use of gadolinium texaphyrin with MRI may improve the ability to detect the extent of gliomas.
- Trial name
- NCT00003410
- Testing
- motexafin gadolinium, magnetic resonance imaging, surgical procedure
- Where
- United States
- Sponsor
- Jonsson Comprehensive Cancer Center
Neuroendocrine Tumors, Carcinoma, Small Cell Lung
PEN-221 in Somatostatin Receptor 2 Expressing Advanced Cancers Including Neuroendocrine and Small Cell Lung Cancers
Protocol PEN-221-001 is an open-label, multicenter Phase 1/2a study evaluating PEN-221 in patients with SSTR2 expressing advanced gastroenteropancreatic (GEP) or lung or thymus or other neuroendocrine tumors or small cell lung…
- Conditions
- Neuroendocrine Tumors, Carcinoma, Small Cell Lung, Neuroendocrine Carcinoma
- Trial name
- NCT02936323
- Testing
- PEN-221
- Where
- 13 sites in United States, United Kingdom
- Volunteers
- 89 people
- Sponsor
- Tarveda Therapeutics
Neuroblastoma
Interleukin-2 in Treating Children With Stage IV Neuroblastoma Who Have Received Induction Therapy and Peripheral Stem Cell Transplantation
RATIONALE: Interleukin-2 may stimulate a person's white blood cells to kill neuroblastoma cells. PURPOSE: Phase II trial to study the effectiveness of interleukin-2 in treating children with stage IV neuroblastoma who have…
- Trial name
- NCT00003743
- Testing
- aldesleukin
- Where
- Austria
- Volunteers
- 25 people
- Sponsor
- St. Anna Kinderkrebsforschung
Glioblastoma
VXM01 Phase I Pilot Study in Patients With Operable Recurrence of a Glioblastoma
VXM01 phase I pilot study in patients with operable recurrence of a glioblastoma to examine safety, tolerability, immune and biomarker response to the investigational VEGFR-2 DNA vaccine VXM01
- Trial name
- NCT02718443
- Testing
- VXM01
- Where
- Germany
- Volunteers
- 14 people
- Sponsor
- Vaximm GmbH
Uveal Melanoma, Ocular Melanoma
Olaparib in Combination With Pembrolizumab for Advanced Uveal Melanoma
This is a prospective phase II multi-center trial of the combination of the PARP inhibitor olaparib with the immune checkpoint inhibitor pembrolizumab in advanced uveal melanoma.
- Trial name
- NCT05524935
- Testing
- Pembrolizumab, Olaparib
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Melanoma (Skin)
Vaccine Therapy in Treating Patients With Stage II Melanoma That Can Be Removed by Surgery
RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. It is not yet known what preparation of vaccine therapy is most effective for treating melanoma.
- Trial name
- NCT00003274
- Testing
- gp100 antigen, incomplete Freund's adjuvant, sargramostim
- Where
- 2 sites in United States
- Volunteers
- 48 people
- Sponsor
- University of Southern California
Medullary Thyroid Carcinoma
Study of Anlotinib in Patients With Medullary Thyroid Carcinoma(ALTER01031)
To compare the effects and safety of Anlotinib with placebo in patients with Medullary Thyroid Carcinoma.
- Trial name
- NCT02586350
- Testing
- Anlotinib
- Where
- 19 sites in China
- Volunteers
- 91 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Metastatic Melanoma, Malignant Melanoma
IFN-Gamma Expression as a Predictor of Response to Immune Checkpoint Inhibitors in First-Line Metastatic Melanoma
This study evaluates whether interferon-gamma (IFN-γ) expression in tumor tissue and peripheral blood can serve as a predictive biomarker of response to immune checkpoint inhibitors in the first-line treatment of metastatic…
- Conditions
- Metastatic Melanoma, Malignant Melanoma, Skin Cancer
- Trial name
- MAK (NCT07436390)
- Testing
- Pembrolizumab, Nivolumab, Ipilimumab/Nivolumab
- Where
- Slovenia
- Volunteers
- 132 people
- Sponsor
- Institute of Oncology Ljubljana
Melanoma (Skin)
Dasatinib in Treating Patients With Locally Advanced or Metastatic Mucosal Melanoma, Acral Melanoma, or Vulvovaginal Melanoma That Cannot Be Removed By Surgery
RATIONALE: Dasatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well dasatinib works in treating patients with locally advanced or…
- Trial name
- NCT00700882
- Testing
- dasatinib
- Where
- 153 sites in United States
- Volunteers
- 81 people
- Sponsor
- Eastern Cooperative Oncology Group